Prostate Cancer
EA8191 / INDICATE
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Patient Educational Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.
This video provides an overview of the EA8191/INDICATE research study for men with prostate cancer that has returned after surgery.
This video describes what will happen for patients in the PET-negative group of the EA8191/INDICATE research study. This study is for men with prostate cancer that has returned after surgery. The PET-negative group includes patients who have no metastases detectable outside the pelvis on their PET scan.
This video describes what will happen for patients in the PET-positive group of the EA8191/INDICATE research study. This study is for men with prostate cancer that has returned after surgery. The PET-positive group includes patients who have metastases detectable outside the pelvis on their PET scan (but not detectable on other types of imaging).
Recruitment/Awareness Promotional Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. Note: this content can be utilized for site-specific and community outreach (e.g., webpages, informational handouts, posters, etc.) to encourage potential participants to talk with their doctor, or to contact a site where the study is open for more information. The content may not be modified, and the entities who implement this plan (not including clinical staff) must refrain from direct engagement with patients, except to encourage them to speak with their doctor, or to direct them to the trial page on ECOG-ACRIN or Cancer.gov.
